Cargando…
Promising molecular mechanisms responsible for gemcitabine resistance in cancer
Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Chongqing Medical University
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150077/ https://www.ncbi.nlm.nih.gov/pubmed/30258872 http://dx.doi.org/10.1016/j.gendis.2015.07.003 |